000305336 001__ 305336
000305336 005__ 20251014115439.0
000305336 0247_ $$2doi$$a10.1002/ijc.70192
000305336 0247_ $$2pmid$$apmid:41074584
000305336 0247_ $$2ISSN$$a0020-7136
000305336 0247_ $$2ISSN$$a1097-0215
000305336 037__ $$aDKFZ-2025-02080
000305336 041__ $$aEnglish
000305336 082__ $$a610
000305336 1001_ $$00000-0001-5521-0089$$aBing, Xin$$b0
000305336 245__ $$aUsing period analysis for timely assessment and prediction of 5-year relative survival for childhood cancer patients from Taizhou, Eastern China.
000305336 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000305336 3367_ $$2DRIVER$$aarticle
000305336 3367_ $$2DataCite$$aOutput Types/Journal article
000305336 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1760364490_16112
000305336 3367_ $$2BibTeX$$aARTICLE
000305336 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305336 3367_ $$00$$2EndNote$$aJournal Article
000305336 500__ $$aepub
000305336 520__ $$aTimely population-based cancer registry data with accurate 5-year relative survival (RS) estimates is essential for childhood cancer control. This study analyzed survival patterns and projected future trends using data from nine cancer registries in Taizhou, Eastern China, covering patients under 15 years diagnosed during 2004-2023. Period analysis methods were employed to calculate overall and stratified 5-year RS by sex, region, age at diagnosis, and cancer types, with model-based projections for 2024-2028. The 2019-2023 overall 5-year RS reached 80.0%, showing comparable rates between females (80.8%) and males (79.6%) but significant urban-rural disparity (urban: 83.9% vs. rural: 78.6%). Survival rates followed an age-specific pattern, peaking at 84.8% in 5- to 9-year-olds before decreasing to 75.9% in 10- to 14-year-olds. Projections estimate an overall 5-year RS of 82.2% for 2024-2028. As China's first application of period analysis in childhood cancer surveillance, this study provides crucial baseline data demonstrating 80.0% 5-year RS during 2019-2023 and predicting 82.2% for 2024-2028 in Taizhou. These findings provide essential data for evaluating the effectiveness of childhood cancer early detection and screening initiatives in Eastern China. The methodology establishes a framework for ongoing survival monitoring to inform pediatric cancer control strategies.
000305336 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000305336 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000305336 650_7 $$2Other$$a5‐year relative survival
000305336 650_7 $$2Other$$aEastern China
000305336 650_7 $$2Other$$acancer registry
000305336 650_7 $$2Other$$achildhood cancers
000305336 650_7 $$2Other$$aperiod analysis
000305336 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000305336 7001_ $$00000-0002-7575-3627$$aZhao, Xiaojiao$$b2
000305336 7001_ $$0P:(DE-He78)597aa299c1fd0d1502efbfb3894ad3c9$$aLei, Qiqi$$b3$$udkfz
000305336 7001_ $$aWang, Liangyou$$b4
000305336 7001_ $$aZhang, Luyao$$b5
000305336 7001_ $$aChen, Xukai$$b6
000305336 7001_ $$aYang, Jun$$b7
000305336 7001_ $$aChen, Tianhui$$b8
000305336 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.70192$$gp. ijc.70192$$pnn$$tInternational journal of cancer$$vnn$$x0020-7136$$y2025
000305336 909CO $$ooai:inrepo02.dkfz.de:305336$$pVDB
000305336 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000305336 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)597aa299c1fd0d1502efbfb3894ad3c9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000305336 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000305336 9141_ $$y2025
000305336 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000305336 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-17$$wger
000305336 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000305336 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000305336 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000305336 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000305336 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000305336 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000305336 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000305336 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000305336 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000305336 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2024-12-17
000305336 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2024-12-17
000305336 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000305336 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000305336 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Krebsprävention und Survivorship$$x2
000305336 980__ $$ajournal
000305336 980__ $$aVDB
000305336 980__ $$aI:(DE-He78)B062-20160331
000305336 980__ $$aI:(DE-He78)HD01-20160331
000305336 980__ $$aI:(DE-He78)C110-20160331
000305336 980__ $$aUNRESTRICTED